Experienced in Streptococcal Group A Infection

Jiro Fujita

Ohama, JP 
Experienced in Streptococcal Group A Infection
Ohama, JP 
OverviewLocationsClinical Research

Overview

Jiro Fujita practices in Ohama, Japan. Mr. Fujita is rated as an Experienced expert by MediFind in the treatment of Streptococcal Group A Infection. His top areas of expertise are Pneumonia, Pyogenic Liver Abscess, Flu, Endoscopy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 316 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Streptococcal Group A Infection.

Gender
Male

Locations

Ohama, Japan
Other Locations
Obama, Japan
Suita, 5650871, Japan
Naha, 9000005, Japan
Osaka, Japan
Okinawa, Japan
Ginowan, Japan
Uehara, 9030215, Japan
Nakagami, Japan
Nishihara, Japan
Japan
Yonashiro-nishihara, 9030215, Japan
Sakai, Japan
Okazaki, 4801195, Japan
Tokyo, Japan
Aja, 9030215, Japan
Tokeshi, 9030215, Japan
Nagoya, Japan
Tsukuba, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3

316 Total Publications

Evaluation of mlstverse system for accurate subspecies identification and drug resistance prediction in Mycobacterium abscessus species.
Evaluation of mlstverse system for accurate subspecies identification and drug resistance prediction in Mycobacterium abscessus species.
Journal: Microbiology spectrum
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fujita's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 100 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile